Atlas Trials

Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors

Clinical trial NCT05249114 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05249114
Sponsor
Providence Health & Services
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Neuroendocrine Tumors
Start date
2022-12-28
Primary completion
2027-12-01
Enrollment
6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.